SK129897A3 - Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process - Google Patents

Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process Download PDF

Info

Publication number
SK129897A3
SK129897A3 SK1298-97A SK129897A SK129897A3 SK 129897 A3 SK129897 A3 SK 129897A3 SK 129897 A SK129897 A SK 129897A SK 129897 A3 SK129897 A3 SK 129897A3
Authority
SK
Slovakia
Prior art keywords
hydroxy
formula
acetamide
phenyl
phenylethyl
Prior art date
Application number
SK1298-97A
Other languages
English (en)
Slovak (sk)
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK129897A3 publication Critical patent/SK129897A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
SK1298-97A 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process SK129897A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (1)

Publication Number Publication Date
SK129897A3 true SK129897A3 (en) 1998-11-04

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1298-97A SK129897A3 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process

Country Status (35)

Country Link
US (2) US5952369A (de)
EP (1) EP0817772B1 (de)
JP (1) JP3035356B2 (de)
KR (1) KR100258657B1 (de)
AP (1) AP625A (de)
AR (1) AR002729A1 (de)
AT (1) ATE231840T1 (de)
AU (1) AU693336B2 (de)
BG (1) BG62611B1 (de)
BR (1) BR9607750A (de)
CA (1) CA2213815C (de)
CZ (1) CZ306497A3 (de)
DE (1) DE69626009T2 (de)
DK (1) DK0817772T3 (de)
ES (1) ES2188743T3 (de)
HR (1) HRP960141A2 (de)
HU (1) HUP9900767A3 (de)
IL (2) IL117440A0 (de)
IS (1) IS4547A (de)
LV (1) LV11971B (de)
MA (1) MA23832A1 (de)
NO (1) NO974513D0 (de)
NZ (1) NZ304113A (de)
OA (1) OA10518A (de)
PE (1) PE43397A1 (de)
PL (1) PL322652A1 (de)
RU (1) RU2144917C1 (de)
SI (1) SI9620039A (de)
SK (1) SK129897A3 (de)
TN (1) TNSN96045A1 (de)
TR (1) TR199701082T1 (de)
TW (1) TW408111B (de)
WO (1) WO1996030339A1 (de)
YU (1) YU18696A (de)
ZA (1) ZA962476B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規n―置換ピロリジン誘導体及びその製造法
JP2000507970A (ja) * 1997-01-10 2000-06-27 メルク エンド カンパニー インコーポレーテッド キラルメディエータの効率的な合成
EP0982297A3 (de) * 1998-08-24 2001-08-01 Pfizer Products Inc. Verfahren zur Herstellung von Hydroxy-pyrrolidinyl Hydroxamsäure Derivaten, die kappa Opioid-Rezeptor Agonisten sind
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
AU2002247886A1 (en) 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
DK2822928T3 (en) * 2012-03-05 2019-03-11 Dr Reddys Laboratories Ltd SUBSTITUTED HETEROCYCLIC ACETAMIDS AS CAPE-OPIOID RECEPTOR (CHOR) AGONISTS
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
YU18696A (sh) 1999-06-15
HRP960141A2 (en) 1997-10-31
BG101896A (en) 1999-01-29
DK0817772T3 (da) 2003-05-19
LV11971A (lv) 1998-02-20
KR100258657B1 (ko) 2000-07-01
NO974513L (no) 1997-09-29
JP3035356B2 (ja) 2000-04-24
OA10518A (en) 2002-04-22
IS4547A (is) 1997-08-19
MX9707454A (es) 1998-07-31
TNSN96045A1 (fr) 2005-03-15
IL117440A0 (en) 1996-07-23
PL322652A1 (en) 1998-02-16
EP0817772A1 (de) 1998-01-14
AU5121196A (en) 1996-10-16
AP625A (en) 1997-12-24
NO974513D0 (no) 1997-09-29
ATE231840T1 (de) 2003-02-15
WO1996030339A1 (en) 1996-10-03
BG62611B1 (bg) 2000-03-31
PE43397A1 (es) 1997-10-13
DE69626009D1 (de) 2003-03-06
AR002729A1 (es) 1998-04-29
EP0817772B1 (de) 2003-01-29
HUP9900767A3 (en) 2001-01-29
CA2213815A1 (en) 1996-10-03
JPH11501048A (ja) 1999-01-26
MA23832A1 (fr) 1996-10-01
US5952369A (en) 1999-09-14
CA2213815C (en) 2001-12-18
RU2144917C1 (ru) 2000-01-27
IL129479A0 (en) 2000-02-29
TR199701082T1 (xx) 1998-02-21
ZA962476B (en) 1997-09-29
HUP9900767A2 (hu) 1999-07-28
ES2188743T3 (es) 2003-07-01
US6110947A (en) 2000-08-29
TW408111B (en) 2000-10-11
AP9600791A0 (en) 1996-04-30
BR9607750A (pt) 1998-06-30
CZ306497A3 (cs) 1998-07-15
SI9620039A (sl) 1998-08-31
DE69626009T2 (de) 2003-08-14
LV11971B (en) 1998-06-20
KR19980703476A (ko) 1998-11-05
NZ304113A (en) 1999-01-28
AU693336B2 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
RU2125041C1 (ru) Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения
SK129897A3 (en) Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process
SK278434B6 (en) 3-substituted pyrolidine derivative, preparation method thereof, intermediate products of this method, pharmaceutical composition containing this derivative
EP0629190A1 (de) Verbindungen als calcium kanal antagoniste
WO1992022527A2 (en) 3-substituted pyrrolidine derivatives as calcium channel antagonists
JP2935899B2 (ja) ▲下k▼レセプターアゴニストとしてのn−(2−(ピロリジニル−1)−1−フェニルエチル)アセトアミド
GB2068373A (en) Cyclohexene derivatives
Hussaini et al. 2, 5-Disubstituted pyrrolidines: synthesis by enamine reduction and subsequent regioselective and diastereoselective alkylations
US5387688A (en) Intermediates for making analgesic N-phenyl-N-(3-OR1 -3-Me-4-piperidinyl)amides
JP3245578B2 (ja) ピロリジニルヒドロキサム酸化合物の製造方法
NZ233002A (en) 3-(aminoalkyl)benzothiopyran derivatives and pharmaceutical compositions
EP0782989A1 (de) Indol-derivate
EP0789021B1 (de) Hydroxamsäuren als Kappa-Opiat-Rezeptoragonisten
US5716936A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
MXPA97007454A (en) Hydroxamic pirrolidinil acid compounds and their product procedure
EP0097628A2 (de) Piperidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US5130321A (en) Analgesic n-phenyl-n-(3-or 1-3-me-4-piperidinyl)amides
WO2002088082A2 (en) Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
PT789021E (pt) Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao
CZ9902390A3 (cs) Způsob výroby derivátů pyrrolidinylhydroxamové kyseliny